Survival benefit in advanced or metastatic breast cancer with visceral metastases

This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.

Gynecologists and physicians, in concert with mothers, are key not only to a woman’s early awareness of both breast cancer and mammography but to awareness of breast cancer risk factors as well.

A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.

A recent study suggests that unconscious or implicit bias may exist when it comes to physicians referring African American patients with breast cancer for genetic counseling and testing.

New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.

Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.